These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31369545)

  • 41. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
    Le Menach A; Boxall N; Amirthalingam G; Maddock L; Balasegaram S; Mindlin M
    Vaccine; 2014 Feb; 32(10):1147-52. PubMed ID: 24440207
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of three different vaccination strategies against measles in Zambian children.
    Dayan GH; Cairns L; Sangrujee N; Mtonga A; Nguyen V; Strebel P
    Vaccine; 2004 Jan; 22(3-4):475-84. PubMed ID: 14670330
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevaccination antibody screening and immunization program for healthcare personnel against measles, mumps, rubella, and varicella in a Japanese tertiary care hospital.
    Kanamori H; Tokuda K; Ikeda S; Endo S; Ishizawa C; Hirai Y; Takahashi M; Aoyagi T; Hatta M; Gu Y; Yano H; Weber DJ; Kaku M
    Tohoku J Exp Med; 2014 Oct; 234(2):111-6. PubMed ID: 25224029
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review.
    Saokaew S; Rayanakorn A; Wu DB; Chaiyakunapruk N
    Pharmacoeconomics; 2016 Dec; 34(12):1211-1225. PubMed ID: 27510721
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccines for measles, mumps and rubella in children.
    Demicheli V; Jefferson T; Rivetti A; Price D
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004407. PubMed ID: 16235361
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness evaluation of measles immunization strategies on a college campus.
    Shlian DM; Matchar D; Seymann GB
    Fam Pract Res J; 1991 Jun; 11(2):193-207. PubMed ID: 1905455
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Field evaluation of the clinical effectiveness of vaccines against pertussis, measles, rubella and mumps. The Benevento and Compobasso Pediatricians Network for the Control of Vaccine-Preventable Diseases.
    Vaccine; 1998 May; 16(8):818-22. PubMed ID: 9627939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Immunization Programme and Coverage against Measles and Rubella in Spain. Challenges for Achieving their Elimination].
    Limia Sánchez A; Molina Olivas M
    Rev Esp Salud Publica; 2015; 89(4):357-64. PubMed ID: 26580791
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?
    Celikbas A; Ergonul O; Aksaray S; Tuygun N; Esener H; Tanir G; Eren S; Baykam N; Guvener E; Dokuzoguz B
    Am J Infect Control; 2006 Nov; 34(9):583-7. PubMed ID: 17097453
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: analysis of vaccine efficacy and cost-effectiveness.
    Ödemiş Í; Köse Ş; Akbulut Í; Albayrak H
    Rev Esp Quimioter; 2019 Dec; 32(6):525-531. PubMed ID: 31642641
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-benefit calculations of vaccinations against measles and mumps in Austria.
    Wiedermann G; Ambrosch F
    Dev Biol Stand; 1979; 43():273-7. PubMed ID: 118067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Health economics of rubella: a systematic review to assess the value of rubella vaccination.
    Babigumira JB; Morgan I; Levin A
    BMC Public Health; 2013 Apr; 13():406. PubMed ID: 23627715
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A game dynamic model for vaccine skeptics and vaccine believers: measles as an example.
    Shim E; Grefenstette JJ; Albert SM; Cakouros BE; Burke DS
    J Theor Biol; 2012 Feb; 295():194-203. PubMed ID: 22108239
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Economic Costs of Measles Outbreak in the Netherlands, 2013-2014.
    Suijkerbuijk AW; Woudenberg T; Hahné SJ; Nic Lochlainn L; de Melker HE; Ruijs WL; Lugnér AK
    Emerg Infect Dis; 2015 Nov; 21(11):2067-9. PubMed ID: 26488199
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A model to estimate the potential economic benefits of measles eradication for the United States.
    Miller MA; Redd S; Hadler S; Hinman A
    Vaccine; 1998 Dec; 16(20):1917-22. PubMed ID: 9796043
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Measles immunization of 2-year-olds in a rural southern state.
    Feldman S; Andrew M; Gilbert J; Bracken B; Thompson FE
    JAMA; 1994 May; 271(18):1417-20. PubMed ID: 8176803
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resurgence of measles and mumps: not just a childhood problem.
    Nageswaran P; Jenner L; Paul SP
    Br J Nurs; 2017 Apr; 26(8):471. PubMed ID: 28453330
    [No Abstract]   [Full Text] [Related]  

  • 58. Modeling the economic impact of different vial-opening thresholds for measles-containing vaccines.
    Wedlock PT; Mitgang EA; Oron AP; Hagedorn BL; Leonard J; Brown ST; Bakal J; Siegmund SS; Lee BY
    Vaccine; 2019 Apr; 37(17):2356-2368. PubMed ID: 30914223
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
    N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The costs of preventing measles.
    Nassau RD
    JAMA; 1992 Feb; 267(5):655-6. PubMed ID: 1731130
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.